10/774,415

FILE COVERS 1907 - 12 Mar 2003 VOL 138 ISS 11
FILE LAST UPDATED: 11 Mar 2003 (20030311/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s us 6482848/pn
L1 3 US 6482848/PN
(US6482848/PN)

=> s l1
L2 3 US 6482848/PN
(US6482848/PN)

=> select l1
ENTER ANSWER NUMBER OR RANGE (1-):3
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E37 ASSIGNED

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.20	5.41

FILE 'REGISTRY' ENTERED AT 11:13:46 ON 12 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2003 HIGHEST RN 497913-82-3
DICTIONARY FILE UPDATES: 11 MAR 2003 HIGHEST RN 497913-82-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s e1-e31
1 106-89-8/BI
(106-89-8/RN)
1 108-49-6/BI
(108-49-6/RN)
1 109-01-3/BI
(109-01-3/RN)
1 111-95-5/BI
(111-95-5/RN)
1 123-75-1/BI
(123-75-1/RN)

Kamal Saeed

10/794,405

10243942

1 147-85-3/BI
(147-85-3/RN)
1 15285-59-3/BI
(15285-59-3/RN)
1 1892-57-5/BI
(1892-57-5/RN)
1 2199-51-1/BI
(2199-51-1/RN)
1 2199-59-9/BI
(2199-59-9/RN)
1 253870-02-9/BI
(253870-02-9/RN)
1 2917-91-1/BI
(2917-91-1/RN)
1 326914-13-0/BI
(326914-13-0/RN)
1 356068-86-5/BI
(356068-86-5/RN)
1 356068-89-8/BI
(356068-89-8/RN)
1 372092-80-3/BI
(372092-80-3/RN)
1 375387-20-5/BI
(375387-20-5/RN)
1 375798-45-1/BI
(375798-45-1/RN)
1 375798-46-2/BI
(375798-46-2/RN)
1 375798-47-3/BI
(375798-47-3/RN)
1 375798-48-4/BI
(375798-48-4/RN)
1 375798-49-5/BI
(375798-49-5/RN)
1 375798-50-8/BI
(375798-50-8/RN)
1 375798-51-9/BI
(375798-51-9/RN)
1 375798-52-0/BI
(375798-52-0/RN)
1 375798-53-1/BI
(375798-53-1/RN)
1 375798-54-2/BI
(375798-54-2/RN)
1 375798-55-3/BI
(375798-55-3/RN)
1 443-69-6/BI
(443-69-6/RN)
1 498-63-5/BI
(498-63-5/RN)
1 56341-41-4/BI
(56341-41-4/RN)

L3 31 (106-89-8/BI OR 108-49-6/BI OR 109-01-3/BI OR 111-95-5/BI OR 123-75-1/BI OR 147-85-3/BI OR 15285-59-3/BI OR 1892-57-5/BI OR 2199-51-1/BI OR 2199-59-9/BI OR 253870-02-9/BI OR 2917-91-1/BI OR 326914-13-0/BI OR 356068-86-5/BI OR 356068-89-8/BI OR 372092-80-3/BI OR 375387-20-5/BI OR 375798-45-1/BI OR 375798-46-2/BI OR 375798-47-3/BI OR 375798-48-4/BI OR 375798-49-5/BI OR 375798-50-8/BI OR 375798-51-9/BI OR 375798-52-0/BI OR 375798-53-1/BI OR 375798-54-2/BI OR 375798-55-3/BI OR 443-69-6/BI OR 498-63-5/B

10243942

I OR 56341-41-4/BI)

=> d scan

Kamal Saeed

10243942

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2-Propanol, 1-chloro-3-(diethylamino)- (6CI, 7CI, 8CI, 9CI)
MF C7 H16 Cl N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(2-(methoxymethyl)-1-pyrrolidinyl)methyl]-, (3Z)- (9CI)
MF C22 H27 N3 O3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN L-Proline (9CI)
MF C5 H9 N O2
CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzeneacetic acid, 2-amino-5-fluoro-, hydrazide (9CI)
MF C8 H10 F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Kamal Saeed

10243942

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(hydroxymethyl)-, (3Z)- (9CI)
MF C16 H16 N2 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Pyrrole-3-carboxylic acid, 5-formyl-2,4-dimethyl-, ethyl ester (9CI)
MF C10 H13 N O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(2-hydroxy-1-pyrrolidinyl)methyl]-, (3Z)- (9CI)
MF C20 H23 N3 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Ethanamine, 2-methoxy-N-(2-methoxyethyl)- (9CI)
MF C6 H15 N O2
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
MF C22 H27 F N4 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 1-[[bis(2-methoxyethyl)amino]methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI)
MF C22 H29 N3 O3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl- (9CI)
MF C8 H17 N3
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, (3Z)- (9CI)
MF C21 H26 N4 O
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10243942

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Piperazine, 2,6-dimethyl- (7CI, 8CI, 9CI)
MF C6 H14 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 5-fluoro-1,3-dihydro- (9CI)
MF C8 H6 F N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN L-Proline,
1-[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]- (9CI)
MF C21 H23 N3 O3

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Indole-2,3-dione, 5-fluoro- (9CI)
MF C8 H4 F N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10243942

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Kinase (phosphorylating), protein (9CI)
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Pyrrole-1-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
MF C23 H29 F N4 O3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Oxiranemethanamine, N,N-diethyl- (9CI)
MF C7 H15 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(2-methyl-1-pyrrolidinyl)methyl]-, (3Z)- (9CI)
MF C21 H25 N3 O

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10243942

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Pyrrolidine (8CI, 9CI)
MF C4 H9 N
CI COM, RPS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-formyl-2,4-dimethyl- (9CI)
MF C14 H23 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Pyridinium, 1-[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]-, chloride (9CI)
MF C21 H20 N3 O . Cl

Double bond geometry as shown.



● Cl⁻

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Pyrrole-3-carboxylic acid, 2,4-dimethyl-, ethyl ester (9CI)
MF C9 H13 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10243942

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, dihydrochloride, (3Z)- (9CI)
MF C21 H26 N4 O . 2 Cl H

Double bond geometry as shown.



●2 HCl

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Piperazine, 1-methyl- (8CI, 9CI)
MF C5 H12 N2
CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Pyrrole-3-carboxylic acid, 5-formyl-2,4-dimethyl- (9CI)
MF C8 H9 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 1-[(3,5-dimethyl-1-piperazinyl)methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI)
MF C22 H28 N4 O

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10243942

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2-Pyrrolidinemethanol (6CI, 7CI, 8CI, 9CI)
MF C5 H11 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(1-pyrrolidinylmethyl)-, (3Z)- (9CI)
MF C20 H23 N3 O

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 31 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Oxirane, (chloromethyl)- (9CI)
MF C3 H5 Cl O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

Kamal Saeed

```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.80       6.21

STN INTERNATIONAL LOGOFF AT 11:14:55 ON 12 MAR 2003
```

Kamal Saeed

10/724,915

~~10243942~~

ENERGY, INSPEC
NEWS 43 Feb 13 CANCERLIT is no longer being updated
NEWS 44 Feb 24 METADEX enhancements
NEWS 45 Feb 24 PCTGEN now available on STN
NEWS 46 Feb 24 TEMA now available on STN
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 48 Feb 26 PCTFULL now contains images
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:27:04 ON 12 MAR 2003

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:27:10 ON 12 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2003 HIGHEST RN 497913-82-3
DICTIONARY FILE UPDATES: 11 MAR 2003 HIGHEST RN 497913-82-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

Kamal Saeed

```
10243942

http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\Stnexp\Queries\10243942.str

L1      STRUCTURE UPLOADED

=> que L1

L2   QUE L1

=> S L1 FULL
FULL SEARCH INITIATED 11:33:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   3431 TO ITERATE

100.0% PROCESSED    3431 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA SSS FUL L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\Stnexp\Queries\10243942.str

L4      STRUCTURE UPLOADED

=> que L4

L5   QUE L4

=> D
L5 HAS NO ANSWERS
L4               STR
```

10243942



Structure attributes must be viewed using STN Express query preparation.
L5 QUE ABB=ON PLU=ON L4

=> S L4 FULL
FULL SEARCH INITIATED 11:34:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3431 TO ITERATE

100.0% PROCESSED 3431 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L4

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\10243942.str

L7 STRUCTURE UPLOADED

=> que L7

L8 QUE L7

=> D
L8 HAS NO ANSWERS
L7 STR

10243942



Structure attributes must be viewed using STN Express query preparation.
L8 QUE ABB=ON PLU=ON L7

=> S L7 FULL
FULL SEARCH INITIATED 11:36:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5268 TO ITERATE

100.0% PROCESSED 5268 ITERATIONS 1860 ANSWERS
SEARCH TIME: 00.00.01

L9 1860 SEA SSS FUL L7

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	449.65	449.86

FILE 'CAPLUS' ENTERED AT 11:36:51 ON 12 MAR 2003

FILE COVERS 1907 - 12 Mar 2003 VOL 138 ISS 11
FILE LAST UPDATED: 11 Mar 2003 (20030311/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L9
L10 128 L9

10243942

=> FILE REG
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.83	450.69

FILE 'REGISTRY' ENTERED AT 11:38:08 ON 12 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2003 HIGHEST RN 497913-82-3
DICTIONARY FILE UPDATES: 11 MAR 2003 HIGHEST RN 497913-82-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\10243942.str

L11 STRUCTURE UPLOADED

=> que L11

L12 QUE L11

=> D
L12 HAS NO ANSWERS
L11 STR



Kamal Saeed

10243942

Structure attributes must be viewed using STN Express query preparation.
L12 QUE ABB=ON PLU=ON L11

=> S L11 FULL
FULL SEARCH INITIATED 11:38:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3074 TO ITERATE

100.0% PROCESSED 3074 ITERATIONS 1860 ANSWERS
SEARCH TIME: 00.00.01

L13 1860 SEA SSS FUL L11

=> FILE REG
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 148.55 599.24

FILE 'REGISTRY' ENTERED AT 11:39:18 ON 12 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2003 HIGHEST RN 497913-82-3
DICTIONARY FILE UPDATES: 11 MAR 2003 HIGHEST RN 497913-82-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\10243942.str

L14 STRUCTURE UPLOADED

=> que L14

L15 QUE L14

=> D
L15 HAS NO ANSWERS
L14 STR

10243942



Structure attributes must be viewed using STN Express query preparation.
L15 QUE ABB=ON PLU=ON L14

=> S L14 FULL
FULL SEARCH INITIATED 11:39:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2980 TO ITERATE

100.0% PROCESSED 2980 ITERATIONS 1282 ANSWERS
SEARCH TIME: 00.00.01

L16 1282 SEA SSS FUL L14

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	747.39

FILE 'CAPLUS' ENTERED AT 11:39:51 ON 12 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Mar 2003 VOL 138 ISS 11
FILE LAST UPDATED: 11 Mar 2003 (20030311/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L14
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...

10243942

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

```
SAMPLE SEARCH INITIATED 11:40:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     134 TO ITERATE

100.0% PROCESSED     134 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1986 TO     3374
PROJECTED ANSWERS:              720 TO     1640

L17          50 SEA SSS SAM L14


L18           8 L17

=> D IBIB ABS HITSTR TOT
```

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:927188 CAPLUS
DOCUMENT NUMBER: 138:14005
TITLE: Preparation of 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
INVENTOR(S): Cui, Jingrong; Rampal, Yudhi; Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 479 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096361	A2	20021205	WO 2002-US16841	20020530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-294544P P	20010530
			US 2001-328408P P	20011010
OTHER SOURCE(S):			MARPAT 138:14005	

GI



I

AB The present invention relates to certain 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. (shown as I; see below for variable definitions; e.g. 2,4-dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-(3Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
(2-diethylaminoethyl)amide) that inhibit kinases (no data), in particular met kinase. Pharmaceutical compns. comprising these compds., methods of treating diseases mediated by kinases using pharmaceutical compns. comprising these compds., and methods of prepg. them are also disclosed. In I, n = 0-2; m = 1-3; R1 and R3 = H or alkyl; R2, R4, and R5 = H, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, alkoxycarbonyl, haloalkoxy, cyano, carboxy, carboxyalkyl, nitro, aryl, aryloxy, heteroaryl, heteroaryloxy, -(alkylene)-CONR10R11, -CONR10R11, or - NR10R11 (R10 is H or alkyl, and R11 is aryl, heteroaryl, heterocycle, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, aralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy, or R10 and R11 together with the N atom to which they are attached combine to form satd. or unsatd. heterocycloamino). R6 is H, alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, heterocyclylalkyl, aryl, heteroaryl, carboxy, alkoxycarbonyl, heterocyclylcarbonyl, aminoalkylcarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarboxyl, -CONR10R11 or -(alkylene)-CONR10R11. R7 and R8 = H, alkyl, cycloalkyl, heterocyclylalkyl, -COR12, -(alkylene)-COR12 (R12 = alkoxy, hydroxy, or heterocycle, alkylamino, dialkylamino), -SO2R14, -CONR13R14, or -(alkylene)-CONR13R14 (R13 is H or alkyl, and R14 is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s), or when R13 and R14 are attached to a N atom R13 and R14 together with the N atom to which they are attached form satd. or unsatd. heterocycloamino). R6 and R7 or R7 and R8 can combine to form a satd. or unsatd. 5 to 8 membered ring; and R9 is: H or alkyl; -PO(OR15)2 where each R15 = H or alkyl; -COR16 where R16 is H or alkyl; or -CHR17NR18R19 where R17 is H or alkyl, and R18 and R19 = H or alkyl or R18 and R19 together with the N atom to which they are attached form heterocycloamino. Although the methods of prepn. are not claimed, 375 example prepns. of I plus addnl. prepns. of intermediates are included.

IT 477573-65-2P, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-methoxyphenylmethanesulfonyl]-1,3-dihydroindol-2-one 477573-87-8P, 5-(4-Bromophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one 477574-08-6P, 5-[5-(3-Chlorophenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 477574-16-0P, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-[4-nitrophenylmethanesulfonyl]-1,3-dihydroindol-2-one 477574-45-1P, 5-[2,3-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
dihydroindol-2-one 477574-75-7P, 3-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide 477574-95-2P, 5-[2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3-[(3-diethylaminopyrrolidin-1-yl]carbonyl]-5-methyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one 477573-04-5P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-(1-[4-[(S)-2-[(R)-3-fluoropyrrolidin-1-yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one 477575-25-6P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one 477575-33-9P, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-methyl-N-(1-methylpiperidin-4-yl)acetamide 477575-56-7P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one 477575-69-2P***, 5-(2,3-Dichlorophenylmethanesulfonyl)-3-[1-[4-[[(2R,5S)-2,5-dimethylpiperazin-1-yl]carbonyl]-2,5-dimethyl-1H-pyrrol-3-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one ***477575-88-5P, 3-[1-[3,5-Dimethyl-4-(2-(piperidin-1-yl)acetyl)-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one 477575-90-9P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-4-yl)ethyl]amide 477576-52-6P, 5-[6-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-cyclopropylamino-2-hydroxypropyl)amide 477576-63-1P, 3-(1-[4-(2-(4-Cyclopropylmethylpiperazin-1-yl)-2-oxoethyl]-2,5-dimethyl-1H-pyrrol-3-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one 477576-95-7P, 5-(5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(4-fluoropiperidin-1-yl)ethyl]amide 477577-09-6P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-[(S)-3-((3-fluoropiperidin-1-yl)methyl]pyrrolidin-1-yl]-2-oxoethyl]-2,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one 477577-56-1P, 3-[1-[4-[[(Cyclopropyl]methylamino]methyl]-3,5-dimethyl-1H-pyrrol-3-yl]meth-(Z)-ylidene]-5-[2-(2-(morpholin-4-yl)ethoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one 477577-66-3P, 5-(5-(2,6-Dichlorophenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (cyclopropylmethyl][(R)-1-pyrrolidin-2-ylmethyl]amide 477577-74-3P, 5-(2-Chlorophenylmethanesulfonyl)-3-[1-(4-[((R)-2-[(cyclopropylamino)methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one 477578-03-2P, 2-[5-(2,6-Dichlorophenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl]amide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
(drug candidate; prepn. of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)

RN 477573-65-2 CAPLUS
CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[(3-methoxyphenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-87-8 CAPLUS
CN Piperazine, 1-[[5-[(Z)-[5-[[(4-bromophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-08-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(3-chlorophenyl)methyl]sulfonyl]-1,2-

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-10-0 CAPLUS
CN Piperazine, 1-[(5-[(Z)-[1,2-dihydro-5-[[(4-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-45-1 CAPLUS
CN Piperazine, 1-[(5-[(Z)-[5-[[(2,3-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477575-04-5 CAPLUS
CN Pyrrolidine, 1-[(5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3-[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-29-4 CAPLUS
CN Piperazine, 1-[(5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477574-75-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 3-[(Z)-[5-[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477574-96-2 CAPLUS
CN 3-Pyrrolidinamine, 1-[[2-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477575-32-9 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-56-7 CAPLUS
CN Pyrrolidine, 1-[(5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477575-69-2 CAPLUS
CN Piperazine, 1-[[5-[(Z)-[5-[[(2,3-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-88-5 CAPLUS
CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-piperidinylacetyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-[(phenylmethyl)sulfonyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477576-65-1 CAPLUS
CN Piperazine, 1-(cyclopropylmethyl)-4-[[5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-95-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(4-fluoro-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477575-90-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-52-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(cyclopropylamino)-2-hydroxypropyl]-5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477577-09-6 CAPLUS
CN Pyrrolidine, 1-[[5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-[(3-fluoro-1-piperidinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-56-1 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(cyclopropylmethylamino)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-[[[2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]sulfonyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477577-66-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(cyclopropylmethyl)-5-[(Z)-[5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-74-5 CAPLUS
CN 2-Pyrrolidinemethanamine, 1-[[5-[(Z)-[5-[[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-N-cyclopropyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 477578-02-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[(2,4-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L18 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:793619 CAPLUS
DOCUMENT NUMBER: 137:294870
TITLE: Preparation of prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinones and activity as modulators of protein kinases
INVENTOR(S): Sun, Connie Li; Wei, Chung Chen; Tang, Peng Cho; Koenig, Marcel; Zhou, Yong; Vojkovsky, Tomas; Nematalla, Asaad S.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081466	A1	20021017	WO 2002-US11001	20020409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282630P P 20010409
OTHER SOURCE(S): MARPAT 137:294870
GI



I

AB The present invention relates to pyrrole substituted 2-indolinone compds. (shown as I; e.g. 3-(1-(),5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydroindole-1-carbonyl chloride) and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer (no data). In I, R1 and R2 are independently H, halo, alkyl, alkylthio, nitro, trihalomethyl, hydroxy, hydroxyalkyl, alkoxy, cyano, aryl, heteroaryl,

L18 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
C(O)R7 (R7 is alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, heterocycle, and aminoalkylamino), -NR8R9, -NR8C(O)R9, -SO2R8, and -S(O)2NR8R9 (R8 and R9 are independently H, alkyl, aryl and heteroaryl, or R8 and R9 together with the N to which they are attached form a satd. heterocycloamino). R3 is H, alkyl, hydroxyalkyl, aminoalkyl, -C(O)R7, aryl, and heteroaryl; R4 is H, alkyl, -C(O)R7 aryl, and heteroaryl. R5 is H and -COR10 where R10 is alkyl, alkoxy, hydroxy, aryl, aryloxy, heteroaryl, heterocycle, alkylamino, dialkylamino, or -NR11R12 where R11 is H or alkyl, and R12 is aminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s); or R4 and R5 together form - (CH2)4- or -(CH2)mCO(CH2)n- wherein n is 0 to 3, provided that n+m is 3. R6 is: (c) -OR13 wherein R13 is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocyclyl, monosaccherides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in said alkyl chain are optionally replaced by O, -NR14- (R14 is H or alkyl), -S-, or -SO2-; or. (d) -NR15R16 where are R15 and R16 are independently H, alkyl, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, aryl, heteroaryl, heteroaralkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in the alkyl chain are optionally replaced by O, -NR17- (R17 is H or alkyl), -S-, or -SO2-; or R15 and R16 together with the N atom to which they are attached form satd. or unsatd. heterocycloamino;. Although the methods of prepn. are not claimed, >60 example prepns. are included, both of I and the unprotected version of I in which the C(O)R6 group has been replaced by H.

IT 468744-92-5P, 3-(1-(2,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydroindole-1-carboxylic acid methyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase modulator prodrug; prepn. of prodrugs of (pyrrolylmethylidene]indolinones and activity as modulators of protein kinases)

RN 468744-92-5 CAPLUS
CN 1H-Indole-1-carboxylic acid, 3-[(2,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-, methyl ester, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 342641-87-6P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide 342641-89-8P, 5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein kinase modulator; prepn. of prodrugs of (pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)

RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:658111 CAPLUS
DOCUMENT NUMBER: 137:185408
TITLE: 3-(4-Amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
INVENTOR(S): Guan, Huiping; Liang, Congxin; Sun, Li; Tang, Peng Cho; Wei, Chung Chen; Mauragis, Michael A.; Vojkovsky, Tomas; Jin, Qingwu; Harrinton, Paul Matthew
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066463	A1	20020829	WO 2002-US4407	20020215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-268683P P	20010215
			US 2001-312361P P	20010815

OTHER SOURCE(S): MARPAT 137:185408
GI

L18 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



I



II

AB Title compds. I [R1 = H, halo, alkyl, haloalkoxy, cycloalkyl, heterocyclic, OH, alkoxy, (un)esterified CO2H, (un)substituted NH2, CONH2; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (un)substituted NH2, SO2NH2, (un)esterified CO2H, SO2R8, R8 = alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; R3-R6 = H, alkyl; R7 = H, alkyl, aryl, heteroaryl, acyl; R = aryl, heteroaryl, heterocyclic, (un)substituted NH2] were prepd. for use as protein kinase inhibitors in treatment of diseases, such as cancer (no data). Thus, Et 3,5-dimethyl-4-pyrrolecarboxylate was oxidized to the 5-carboxaldehyde, followed by ester hydrolysis, reaction with 5-fluoro-2-oxindole and amidation to give the amide II.

IT 452104-49-3P 452104-92-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivs. as protein kinase inhibitors)

RN 452104-49-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 452104-92-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:539677 CAPLUS
DOCUMENT NUMBER: 137:109202
TITLE: Preparation of 4-aryl substituted indolinones as protein kinase signal transduction modulators for inhibiting abnormal cell proliferation
INVENTOR(S): Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung Chen; Tang, Peng Cho
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 560 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055517	A2	20020718	WO 2001-US48564	20011220
WO 2002055517	A3	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-256479P P 20001220
OTHER SOURCE(S): MARPAT 137:109202
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocyclyl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compns. thereof, are prepd. and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepd. via condensation of 4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxylic acid Et ester. I were evaluated against eight specific kinases, e.g., PGFR1, for which I possessed IC50 values [.mu.M] of 0.0091-2.07. The present invention also relates to methods for treating protein kinase related disorders.

IT 442558-30-7P 442558-35-2P 442558-44-3P
442558-59-0P 442558-73-8P 442559-11-7P
442559-21-9P 442559-42-4P 442559-57-1P
442559-65-1P 442561-26-4P 442561-53-7P

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
442561-58-2P 442561-87-7P 442561-89-9P
442562-68-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)

RN 442558-30-7 CAPLUS
CN Piperazine, 1-[[5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-35-2 CAPLUS
CN 3-Pyrrolidinamine, 1-[[2-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-N,N-dimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 442558-44-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-59-0 CAPLUS
CN Piperazine, 1-[[5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 442558-73-8 CAPLUS

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Pyrrole-2-carboxamide,
N-[2-(diethylamino)ethyl]-5-[[4-(3-fluorophenyl)-
1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442559-11-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 442559-21-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-[[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]-
(9CI)
(CA INDEX NAME)

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 442559-42-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442559-57-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 442559-65-1 CAPLUS
CN Piperidine, 1-[[2-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]acetyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-26-4 CAPLUS
CN Pyrrolidine, 1-[(2-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 442561-53-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-58-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(Z)-[4-[2,6-difluorophenyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 442561-87-7 CAPLUS
CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-methyl-4-piperidinyl)-1H-pyrrol-2-yl]methylene]-4-(3-fluorophenyl)-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442561-89-9 CAPLUS
CN 2H-Indol-2-one, 4-(2,3-difluorophenyl)-3-[[3,5-dimethyl-4-(1-methyl-4-piperidinyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 442562-48-3 CAPLUS
CN Piperazine,
1-[[5-[[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:31440 CAPLUS
DOCUMENT NUMBER: 136:103386
TITLE: Preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Wei, Chung Chen; Huang, Ping; Cui, Jingrong
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002551	A1	20020110	WO 2001-US20768	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002187978	A1	20021212	US 2001-894902	20010629

PRIORITY APPLN. INFO.: US 2000-215654P P 20000630
OTHER SOURCE(S): MARPAT 136:103386
GI



AB Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, etc.; Het = (un)substituted arom. heterocycle contg. at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted arom. heterocycle contg. not more than two N atoms, 5-membered ring (un)substituted heterocycle contg. N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.] with some exceptions, were prepd. Included are 75 synthetic examples and results for several protein tyrosine kinase assays for those compds. For instance, 4-bromoindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf).bul.CH2Cl2, 80.degree.C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine.bul.HCl (THF, Pd(PPh3)4, NaOH, 70.degree.C,

L18 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)
6 h) to give the indole which was treated with C5H5N.bul.Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dyhydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.68 nM for FGFR-1 tyrosine kinase and 0.03 nM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.

IT 388116-65-2P 388117-30-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; prepn. and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-65-2 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:617993 CAPLUS
DOCUMENT NUMBER: 135:195497
TITLE: Preparation of pyrrole substituted 3-indolinone protein kinase inhibitors for treatment of cancer
INVENTOR(S): Tang, Peng Cho; Miller, Todd; Li, Xiaoyuan; Sun, Li; Wei, Chung Chen; Shirazian, Shahrzad; Liang, Congxin; Vojkovsky, Tomas; Nemetalla, Asaad S.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060814	A2	20010823	WO 2001-US4813	20010215
WO 2001060814	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002156293	A1	20021024	US 2001-783264	20010215
EP 1255752	A2	20021113	EP 2001-914376	20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2002003831	A	20021015	NO 2002-3831	20020813

PRIORITY APPLN. INFO.: US 2000-182710P P 20000215
US 2000-216422P P 20000706
US 2000-243532P P 20001027
WO 2001-US4813 W 20010215

OTHER SOURCE(S): MARPAT 135:195497
GI

L18 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



I



II

AB The title compds. (I) (wherein R1 = H, halo, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, OH, alkoxy, acyl, (un)substituted amino or carbamoyl, etc.; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (hetero)aryl, (un)substituted amino, acyl(amino), or sulfamoyl, etc.; R3 = H, halo, alkyl, trihalomethyl, OH, alkoxy, (hetero)aryl, (un)substituted acyl, (acyl)amino, sulfamoyl, or alkylsulfonyl, etc.; R4 = H, halo, alkyl, OH, alkoxy, or (un)substituted amino; R5 and R6 = independently H, alkyl, or acyl; R7 = H, alkyl, (hetero)aryl, or acyl; and their pharmaceutically acceptable salts] were prepd. as protein kinase modulators for the treatment of cellular disorders such as cancer. For example, 5-fluoro-1,3-dihydroindol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give II (55%). II exhibited comparable activity against Flk-1 and PDGFR.beta. and inhibited PDGF-dependent receptor phosphorylation in cells with an IC50 value of approx. 0.03 .mu.M. In efficacy expts. against various cancers in mice, II was well tolerated at 80 mg/kg/day, even when dosed continuously for more than 100 days.

IT 342641-87-6P 342641-89-8P 356069-24-4P
356069-41-5P 356069-71-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L18 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-24-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 356069-41-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-71-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L18 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:396655 CAPLUS
DOCUMENT NUMBER: 135:19549
TITLE: Preparation of pyrrole substituted 2-indolinones as antitumor agents
INVENTOR(S): Shenoy, Waman; Sorasuchart, Waranush
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037820	A2	20010531	WO 2000-US32277	20001122
WO 2001037820	A3	20011213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1233941	A2	20020828	EP 2000-982228	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 1999-167544P A1 19991124
WO 2000-US32277 W 20001122

OTHER SOURCE(S): MARPAT 135:19549
GI



I

AB The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, halo, alkyl, etc.; R3-R6 = H, alkyl, trihaloalkyl, etc.; R3 and R4, R4 and R5, R5 and R6 may combine to form a six membered aryl ring, OCH2O, OCH2CH2O; R7 = H, alkyl, cycloalkyl, etc.; R8-R10 = H, alkyl, trihaloalkyl, etc.] were prepd. and formulated. E.g., a multi-step synthesis of I (R1-R7 = H; R8, R10 = Me; R9 = (CH2)2CO2H) which showed 79-86% inhibition of tumor growth of Calu-6 cells in mice at 75 and 100 mg/kg/day, was given. The present invention features formulations of indolinones which compds. are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term "ionizable substituted indolinone" includes pyrrole substituted 2-indolinones I which, in addn. to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compd., are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group.

IT 342641-87-6P 342641-89-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrole substituted 2-indolinones as antitumor agents)

RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 342641-89-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)

L18 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:660816 CAPLUS
DOCUMENT NUMBER: 134:141324
TITLE: Biotransformation of the anti-angiogenic compound SU5416
AUTHOR(S): Antonian, Lida; Zhang, Hongbing; Yang, Cheng; Wagner, Greg; Shawver, Laura K.; Shet, Manjunath; Ogilvie, Brian; Madan, Ajay; Perkinson, Andrew
CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, 94080, USA
SOURCE: Drug Metabolism and Disposition (2000), 28(12), 1505-1512
CODEN: DMDSAI; ISSN: 0090-9556
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB SU5416 [3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one], an inhibitor of VEGF (vascular endothelial growth factor) receptor tyrosine kinase, Flk-1/KDR (fetal liver kinase 1/kinase insert domain-contg. receptor), also known as VEGF receptor 2 (VEGFR2) is in advanced clin. trials for treatment of AIDS-related Kaposi's sarcoma and colorectal and nonsmall cell lung cancers. Since this chem. class has not been studied previously with therapeutic intent, the present study was designed to investigate the in vitro metab. of SU5416 by mouse, rat, dog, monkey, and human liver microsomes and to identify the major metabolites of SU5416. An HPLC procedure was developed and validated to resolve and quantify SU5416 and its metabolites. To evaluate the in vitro metab. of SU5416, pooled liver microsomes from mice, rats, dogs, monkeys, and humans were incubated with SU5416 (25 .mu.M) in the presence of an NADPH-generating system. In the presence of NADPH, mouse, rat, dog, monkey, and human liver microsomes converted SU5416 to at least 12, 9, 9, 7, and 6 polar metabolites, resp. Microsomal metab. of SU5416 showed marked species differences in the levels of diffarent metabolites formed. The overall rate of SU5416 metab. by liver microsomes from the species exaad. followed the rank order: monkey .gtoreq. mouse .apprxeq. rat > dog > human. Two major metabolites of SU5416 were identified, a hydroxymethyl deriv. of SU5416 (M12) and a carboxylic acid deriv. of SU5416 (M6), by spectroscopic methods and comparison with authentic compds. Both of these oxidative metabolites were further metabolized in vivo through glucuronidation. The metabolic fate of SU5416 in microsomes from various species as well as data from in vivo biotransformation in the rat are discussed.

IT 326047-04-3
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(biotransformation of anti-angiogenic compd. SU5416)

RN 326047-04-3 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, [5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L18 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10243942

=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.71	784.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.21	-5.21

STN INTERNATIONAL LOGOFF AT 11:40:34 ON 12 MAR 2003

Kamal Saeed